3 results
Primary:To evaluate the efficacy and safety of anakinra in the treatment of pain in patients with an acute gout attack during 3 days and subsequently assess the effect of anakinra treatment for 21 days in the prevention of recurrent gout attacks.…
The primary objective is reducing treatment-related morbidity and mortality without adversely impacting DFS in Ph+ ALL patients, classified as Standard Risk (SR) based on low minimal residual disease (MRD) at week 10-12 of therapy.Because there is…
To show a non-inferiority of continuous use of oral contraceptives for three months to long term pituitary down-regulation with a GnRH agonist for three months prior to present-day IVF/ICSI protocols in patients with severe endometriosis (ASRM…